SAN-300 is an anti Very late antigen-1 (VLA-1)
MAB. It already has been used in ophthalmology to promote survival of corneal
allografts. Or in 2002
it reduced glomerular and tubulointerstitial scarring in
a rat model of (crescentic) glomerulonephritis. And now
it’s being tested in healthy subjects and patients with active RA, as VLA-1
facilitates migration, proliferation, and retention of lymphocytes and
monocytes/macrophages.
Ch. Inderjeeth and colleagues presented the following study [1439]: “Safety,
Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody
Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers
and Patients With Active Rheumatoid Arthritis.” In “Results” we read: “[…]
The single patient with active RA who received SAN-300 2.0 mg/kg IV met ACR50
at Days 15 and 29 and achieved a good response per EULAR criteria based on
DAS28-CRP at Day 15 (_1.66; absolute score 2.31), and a moderate response at Day
29 (_0.92; 3.05). The placebo patient did not meet criteria for ACR20 or DAS28-CRP
response at any time point. Conclusion: “In this first-in-human study, SAN-300, an antibody against
novel therapeutic target VLA-1, showed nonlinear pharmacokinetics. […] Given
favorable tolerability, encouraging RO [receptor occupancy], and ease of
administration, the SC route of administration warrants investigation in future
multiple-dose studies in patients with active RA.”
When I read
the background I thought that the producer of SAN-300 looks for a new field to
yield fruit. But the results of this phase 1 study warrant further
investigation. Who know, if we’re not going to get another useful drug to fight
RA.
No comments:
Post a Comment